Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

James A. Lofgren, Sripriya Dhandapani, Jason J. Pennucci, Christina M. Abbott, Daniel T. Mytych, Arunan Kaliyaperumal, Steven J. Swanson, Michael C. Mullenix, Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab Journal of Immunology. ,vol. 178, pp. 7467- 7472 ,(2007) , 10.4049/JIMMUNOL.178.11.7467

F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685

Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, Jacques Wils, Lucile Awad, Patrice Herait, Christian Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1407- 1412 ,(1998) , 10.1016/S0140-6736(98)03085-2

D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74

Raphaël Porcher, Vincent Lévy, Sylvie Chevret, Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint Controlled Clinical Trials. ,vol. 23, pp. 650- 661 ,(2002) , 10.1016/S0197-2456(02)00239-8

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M.E. Barugel, Y. Humblet, D. Cunningham, M. Wolf, J.L. Gansert, 10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial Ejc Supplements. ,vol. 7, pp. 6- ,(2009) , 10.1016/S1359-6349(09)72039-7

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019

David Cunningham, Seppo Pyrhönen, Roger D James, Cornelis JA Punt, Tamas F Hickish, Reino Heikkila, Tom B Johannesen, Hans Starkhammar, Clare A Topham, Lucile Awad, Christian Jacques, Patrice Herait, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1413- 1418 ,(1998) , 10.1016/S0140-6736(98)02309-5

Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado, Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 1658- 1664 ,(2007) , 10.1200/JCO.2006.08.1620

W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496